{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.2","upperLimit":"3.9","value":"3.3"},{"groupId":"OG001","lowerLimit":"3.2","upperLimit":"4.6","value":"3.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"500"},{"groupId":"OG001","value":"499"}],"units":"Participants"}],"description":"Time to treatment failure (TTF) is the time from randomization date to date that the decision was made to end the treatment period for any reason; participants who remained in the treatment period at the time of analysis were censored at the date of the last on-study assessment.","dispersionType":"95% Confidence Interval","groups":[{"description":"Cetuximab 400 mg/m\\^2 as an initial dose, followed by 250 mg/m\\^2 intravenously (IV) every 7 days.","id":"OG000","title":"Cetuximab"},{"description":"Panitumumab 6 mg/kg IV every 14 days.","id":"OG001","title":"Panitumumab"}],"paramType":"MEDIAN","populationDescription":"Primary analysis set","reportingStatus":"POSTED","timeFrame":"From randomization until the data cut-off date of 5 February 2013. Maximum time on study was 155 weeks.","title":"Time to Treatment Failure","type":"SECONDARY","unitOfMeasure":"months"}